Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial

被引：1
|
作者：
Park, H. [1 ]
Sanjeevaiah, A. [2 ]
Suresh, R. [1 ]
Mehta, R. [3 ]
Trikalinos, N. [1 ]
Bagegni, N. [1 ]
Aranha, O. [1 ]
Pedersen, K. [1 ]
Nixon, A. [4 ]
Jin, R. [1 ]
Mills, J. [1 ]
Fields, R. [1 ]
Amin, M.
Lim, K.
Tan, B. [1 ]
Grierson, P. [1 ]
Jiang, S. [1 ]
del Rosario, M. [1 ]
Wang-Gillam, A. [1 ]
Lockhart, A. [5 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] UT Southwestern Med Ctr, Dallas, TX USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] Duke Univ, Med Ctr, Durham, NC 27706 USA
[5] Univ Miami, Miller Sch Med, Sylvester Canc Ctr, Miami, FL 33136 USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-131
引用
收藏
页码：S132 / S132
页数：1
相关论文
共 50 条
  • [21] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Cecchini, Michael
    Cleary, James M.
    Shyr, Yu
    Chao, Joseph
    Uboha, Nataliya
    Cho, May
    Shields, Anthony
    Pant, Shubham
    Goff, Laura
    Spencer, Kristen
    Kim, Edward
    Stein, Stacey
    Kortmansky, Jeremy S.
    Canosa, Sandra
    Sklar, Jeffrey
    Swisher, Elizabeth M.
    Radke, Marc
    Ivy, Percy
    Boerner, Scott
    Durecki, Diane E.
    Hsu, Chih-Yuan
    Lorusso, Patricia
    Lacy, Jill
    BRITISH JOURNAL OF CANCER, 2024, 130 (03) : 476 - 482
  • [22] NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma
    Michael Cecchini
    James M. Cleary
    Yu Shyr
    Joseph Chao
    Nataliya Uboha
    May Cho
    Anthony Shields
    Shubham Pant
    Laura Goff
    Kristen Spencer
    Edward Kim
    Stacey Stein
    Jeremy S. Kortmansky
    Sandra Canosa
    Jeffrey Sklar
    Elizabeth M. Swisher
    Marc Radke
    Percy Ivy
    Scott Boerner
    Diane E. Durecki
    Chih-Yuan Hsu
    Patricia LoRusso
    Jill Lacy
    British Journal of Cancer, 2024, 130 : 476 - 482
  • [23] Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interim analysis of a randomized German AIO phase II study.
    Moehler, M.
    Kanzler, S.
    Geissler, M.
    Raedle, J.
    Ebert, M.
    Scherubl, H.
    Flieger, D.
    Seufferlein, T.
    Galle, P. R.
    Hoehler, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 186S - 186S
  • [24] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Strickler, J.
    Nakamura, Y.
    Shitara, K.
    Catenacci, D.
    Janjigian, Y.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H.
    Lee, J.
    Van Cutsem, E.
    Chung, H.
    Tabernero, J.
    Yoshino, T.
    Siena, S.
    Garrido-Mayor, J.
    Palanca-Wessels, M.
    Xie, D.
    Marshall, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S159 - S159
  • [25] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Tabernero, J.
    Strickler, J.
    Nakamura, Y.
    Shitara, K.
    Janjigian, Y.
    Barzi, A.
    Bekaii-Saab, T.
    Lenz, H.
    Yoshino, T.
    Siena, S.
    Garrido-Mayor, J.
    Ubowski, M.
    Xie, D.
    Marshall, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S305 - S306
  • [26] Tolerability and quality-of-life (QoL) results from the phase REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Chau, I.
    Passalacqua, R.
    Zalcberg, J. R.
    Fuchs, C. S.
    Liepa, A. M.
    Hsu, Y.
    Schwartz, J. D.
    Koshiji, M.
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S615 - S615
  • [27] A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer
    Kondo, Rie
    Watanabe, Satoshi
    Shoji, Satoshi
    Ichikawa, Kosuke
    Abe, Tetsuya
    Baba, Junko
    Tanaka, Junta
    Tsukada, Hiroki
    Terada, Masaki
    Sato, Kazuhiro
    Maruyama, Yoshie
    Makino, Masato
    Hirata, Akira
    Tanaka, Hiroshi
    Koya, Toshiyuki
    Yoshizawa, Hirohisa
    Kikuchi, Toshiaki
    ONCOLOGY, 2018, 94 (04) : 223 - 232
  • [28] A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma
    Blanke, CD
    Haller, DG
    Benson, AB
    Rothenberg, ML
    Berlin, J
    Mori, M
    Hsieh, YC
    Miller, LL
    ANNALS OF ONCOLOGY, 2001, 12 (11) : 1575 - 1580
  • [29] Phase II trial of TAK-264 in previously treated patients (pts) with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expression guanylyl cyclase C (GCC)
    Almhanna, Khaldoun
    Miron, Maria Luisa Limon
    Wright, David
    Gracian, Antonio Cubillo
    Hubner, Richard
    Van Laethem, Jean-Luc
    Lopez, Carolina Muriel
    Alsina, Maria
    Munoz, Federico Longo
    Bendell, Johanna
    Messersmith, Wells
    Yang, Huyuan
    Fasanmade, Adedigbo
    Danaee, Hadi
    Kalebic, Thea
    CANCER RESEARCH, 2016, 76
  • [30] Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option
    Park, Haeseong
    Klempner, Samuel J.
    Chao, Joseph
    Wainberg, Zev A.
    Lukanowski, Mariusz
    Chenji, Suresh
    Bourke, Shannon
    Chatterjee, Anindya
    Lorenzen, Sylvie
    FRONTIERS IN ONCOLOGY, 2024, 14
12345